MicroTech Medical (Hangzhou) Co., Ltd. Class H (2235) AI Stock Analysis

• Market Cap: HK$2.86B
• Dividend Yield: N/A
• Average Volume (3M): 239.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: 49.86%
• EPS Growth: 80.35%
• Country: HK
• Employees: 678
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 169,175,840
• 10 Day Avg. Volume: 494,910
• 30 Day Avg. Volume: 239,241
• PEG Ratio: 0.79
• Price to Book (P/B): 1.22
• Price to Sales (P/S): 6.98
• P/FCF Ratio: -11.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$6.60
• Price Target Upside: -7.04% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.05
• Revenue Forecast (FY): HK$583.22M

• Rating: 44 Neutral
• Price Target: HK$6.50 ▼(-8.45% Downside)

MicroTech Medical's overall stock score is primarily impacted by its financial performance, marked by strong revenue growth but significant profitability and cash flow challenges. Technical analysis indicates bearish momentum, and valuation metrics are weak due to a negative P/E ratio. The absence of earnings call data and corporate events leaves these areas unaddressed.

MicroTech Medical (Hangzhou) Co., Ltd. Class H Business Overview & Revenue Model

Company Description

MicroTech Medical (Hangzhou) Co., Ltd. is a leading manufacturer and supplier in the medical device industry, specializing in the development and production of advanced medical technologies and devices. The company operates primarily in the healthcare sector, focusing on innovative solutions for diabetes management, including insulin delivery systems and blood glucose monitoring devices. With a commitment to enhancing patient care and outcomes, MicroTech Medical integrates cutting-edge technology into its products to improve the quality of life for individuals with chronic conditions.

How the Company Makes Money

MicroTech Medical generates revenue primarily through the sale of its medical devices and technology solutions. Key revenue streams include direct sales of insulin delivery systems, blood glucose monitoring devices, and related accessories to hospitals, clinics, and pharmacies. The company also engages in partnerships with healthcare providers and organizations to supply its products, which can further enhance sales volume. Additionally, MicroTech Medical may earn income from research and development agreements, as well as licensing its technology to other medical device manufacturers. Strategic collaborations with healthcare institutions and participation in medical conferences help the company to increase brand visibility and expand its customer base, contributing to overall revenue growth.

MicroTech Medical (Hangzhou) Co., Ltd. Class H Financial Statement Overview

Summary

MicroTech Medical shows strong revenue growth but faces significant profitability challenges. The balance sheet is stable with minimal leverage, yet negative returns on equity and cash flow issues highlight areas needing improvement.

Income Statement

MicroTech Medical has shown a positive revenue growth rate of 17.87% in the latest year, indicating a strong upward trajectory in sales. However, the company continues to face challenges with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively healthy at 52.91%, but the persistent negative net profit margin of -18.26% highlights ongoing cost management issues.

Balance Sheet

The company maintains a very low debt-to-equity ratio of 0.0021, reflecting minimal leverage and a strong equity position. However, the return on equity is negative at -3.20%, indicating inefficiencies in generating returns from shareholders' equity. The equity ratio is robust, suggesting financial stability despite profitability challenges.

Cash Flow

MicroTech Medical's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow to net income ratio is positive at 1.69, indicating some efficiency in converting net income to cash, but the overall cash flow remains negative. The company needs to improve its cash generation capabilities to support growth and operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	317.77M	345.62M	248.35M	173.54M	151.40M	75.28M
Gross Profit	162.57M	182.85M	123.22M	79.66M	70.88M	36.54M
EBITDA	-62.16M	-121.38M	-184.12M	-110.19M	-39.80M	-141.52M
Net Income	-26.53M	-63.12M	-125.02M	-35.04M	-48.18M	-121.01M
Balance Sheet
Total Assets	2.21B	2.15B	2.16B	2.29B	2.33B	777.27M
Cash, Cash Equivalents and Short-Term Investments	1.72B	1.71B	1.89B	2.05B	2.15B	654.99M
Total Debt	30.83M	4.20M	5.06M	717.00K	255.00K	126.00K
Total Liabilities	238.37M	171.72M	97.70M	82.06M	82.48M	48.76M
Stockholders Equity	1.97B	1.97B	2.06B	2.21B	2.25B	728.52M
Cash Flow
Free Cash Flow	118.45M	-203.88M	-181.69M	-137.45M	-62.94M	-35.26M
Operating Cash Flow	76.64M	-120.65M	-153.00M	-107.67M	-44.22M	-9.57M
Investing Cash Flow	-41.22M	121.16M	-540.70M	-965.58M	97.69M	-1.22M
Financing Cash Flow	-19.35M	-33.15M	-23.46M	-20.57M	1.57B	511.28M

MicroTech Medical (Hangzhou) Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2235, the sentiment is Negative. The current price of 7.1 is above the 20-day moving average (MA) of 6.79, below the 50-day MA of 7.39, and above the 200-day MA of 6.56, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 45.78 is Neutral, neither overbought nor oversold. The STOCH value of 92.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2235.

MicroTech Medical (Hangzhou) Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2172	58 Neutral	HK$6.03B	27.23	11.79%	1.55%	-5.18%	-9.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2235	44 Neutral	HK$2.86B	―	-1.39%	―	49.86%	80.35%
2160	43 Neutral	HK$2.70B	509.09	0.22%	―	-4.38%	―
2500	41 Neutral	HK$1.13B	-1.62	-26.80%	―	-8.56%	-14.84%

MicroTech Medical (Hangzhou) Co., Ltd. Class H Corporate Events

MicroTech Medical Expands Insulin Pump Approval to Younger Patients

MicroTech Medical (Hangzhou) Co., Ltd. has announced the approval of its Equil Patch Insulin Pump for use in children and adolescents aged 3-17 by the National Medical Products Administration. This expansion of indication demonstrates the company’s strong research and development capabilities and is expected to enhance its market position in the diabetes treatment industry. The product offers significant advantages over traditional insulin pumps, including improved accuracy, safety, and convenience, which could lead to increased market share and strategic growth.

The most recent analyst rating on (HK:2235) stock is a Sell with a HK$6.60 price target. To see the full list of analyst forecasts on MicroTech Medical (Hangzhou) Co., Ltd. Class H stock, see the HK:2235 Stock Forecast page.

MicroTech Medical Reports Robust Financial Growth in H1 2025

MicroTech Medical reported a substantial increase in its financial performance for the first half of 2025, with operating revenue rising by 63.1% to RMB245.93 million and gross profit increasing by 57.7% to RMB127.04 million. This growth was driven by a 91.5% increase in CGMS sales, both domestically and internationally. The company also significantly reduced its net loss by 93.9% to RMB2.29 million, attributed to expanded sales, improved budget control, and enhanced operational efficiency. Cost-reducing measures led to a notable decrease in selling and administrative expenses relative to revenue, and the company maintained strong cash reserves of RMB1.716 billion.

The most recent analyst rating on (HK:2235) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on MicroTech Medical (Hangzhou) Co., Ltd. Class H stock, see the HK:2235 Stock Forecast page.

MicroTech Medical Announces Upcoming Board Meeting for Interim Results Review

MicroTech Medical (Hangzhou) Co., Ltd. has announced that its board of directors will hold a meeting on August 29, 2025, to review and approve the unaudited interim results for the first half of the year and consider the recommendation of an interim dividend. This meeting could have implications for the company’s financial performance and shareholder returns.

The most recent analyst rating on (HK:2235) stock is a Sell with a HK$4.60 price target. To see the full list of analyst forecasts on MicroTech Medical (Hangzhou) Co., Ltd. Class H stock, see the HK:2235 Stock Forecast page.